A new species of Goniothalamus (Annonaceae) from New Caledonia, representing a significant range extension for the genus

A previously unknown Annonaceae species from the South Pacific island of New Caledonia is described as Goniothalamus dumontetii . This is the first Goniothalamus species reported from the island, and the easternmost record for the genus. It is easily distinguished from its congeners by the shape of the monocarp (flattened elongate with lateral triangular projections), which reflects the shape of the seeds (flattened rhombohedral). The conservation status of the species is evaluated as endangered (EN) using World Conservation Union (IUCN) red list categories, as it is known from only one relatively small population. The interpretation of geological and molecular data suggests that Goniothalamus dispersed to New Caledonia relatively recently, and does not represent a relict of the break-up of Gondwana.  © 2007 The Linnean Society of London, Botanical Journal of the Linnean Society , 2007, 155 , 497–503.     

Papiine herpesvirus 2 as a Predictive Model for Drug Sensitivity of Macacine herpesvirus 1 (Monkey B Virus)

Monkey B virus (Macacine herpesvirus 1; BV) is endemic in macaques. BV (a BSL4 agent) is the primary zoonotic concern for persons working with macaques in research, and human BV infections frequently are fatal. We assessed the use of a BSL2 baboon herpesvirus (Papiine herpesvirus 1; HVP2) for predicting the drug sensitivity of BV by comparing the sensitivity of the 2 viruses to 12 antiherpetic drugs. Plaque reduction assays showed that 4 drugs (HBPG, BVdU, PFA, and BrdU) were ineffective against both viruses. Of the 8 effective drugs, both viruses were most sensitive to TFT, whereas sensitivity to the remaining 7 drugs varied between BV and HVP2 as well as between strains of HVP2. In addition, the efficacy of 5 drugs (ACV, PCV, GCV, CDV, and EDU) was tested by using a murine model. ACV and EDU were completely ineffective against both HVP2 and BV, and high doses of PCV only delayed death by a few days. GCV and CDV both protected mice against death, and CDV also prevented the development of neurologic symptoms. When the initiation of drug therapy was delayed until after virus gained access to the CNS, both GCV and CDV were ineffective. The similarity of the drug sensitivities of HVP2 and BV in both models validates the use of HVP2 as a BSL2 level model that can be used to predict drug sensitivity of BV. The greater efficacy of CDV relative to GCV suggests the potential for use of CDV in the treatment of zoonotic BV infections.Abbreviations: ACV, acyclovir; AraA, 9-β-D-arabinofuranosyl-adenine; BrdU, 5-bromo-2′-deoxyuridine; BV, monkey B virus; BVdU, (E)-5-(2-bromovinyl)-2′-deoxyuridine; CDV, cidofovir; EDU, 5-ethyl-2′-deoxyuridine; GCV, ganciclovir; HBPG, 9-(4-hydroxybutyl)-N²-phenylguanine; HSV, herpes simplex virus; HVP2, Herpesvirus papio 2; IUdR, 5-iodo-2’-deoxyuridine; PCV, penciclovir; PFA, phosphonoformic acid; TFT, trifluorothymidineMacacine herpesvirus 1 (monkey B virus; BV) is an alpha-herpesvirus of macaque monkeys and is closely related to human herpes simplex virus (HSV) types 1 and 2.^8,11,27 Although BV primarily causes asymptomatic or mild, self-limiting disease in healthy macaques, the virus is extremely neurovirulent when transmitted via bites or scratches to other nonmacaque primate species, including humans. Although human infections are not common, approximately 80% of untreated patients die of BV infection, and survivors frequently continue to suffer from neurologic sequelae. As a consequence of its lethality in humans, BV is classified as a BSL4 pathogen³ and is the single most serious zoonotic concern for veterinary and research personnel who work with macaques. The increasing popularity of ecotourism to monkey temples in Southeast Asia, where tourists and wild, BV-infected macaque populations come into direct contact, represents another potential concern for zoonotic BV infections.^9,12,13,21The antiviral drugs recommended for use in treating BV infections all were originally developed for treatment of HSV infections.^4,18 Because the genes encoding the enzymes targeted by these drugs are conserved between these viruses, BV is sensitive to many of these anti-HSV drugs. However, compared with HSV, BV is less sensitive to these drugs.^2,10,14 Although more effective drugs are needed for the treatment of BV infections, the biohazardous nature of and facility requirements associated with studying a BSL4 agent severely limit research on BV. A potential solution to this problem is using a closely related virus whose biologic and molecular properties are very similar to those of BV as a surrogate or model system in which preliminary research can be conducted safely, leaving only confirmative testing to be done with infectious BV.Baboons carry an alpha-herpesvirus (Papiine herpesvirus 2; HVP2) that is biologically and genetically very similar to BV and HSV.^7,8,15,26 In mice, most HVP2 isolates are extremely neurovirulent and closely reflect the pathogenesis of BV in mice^20,23 At the antigenic level, HVP2 and BV are so similar that HVP2 has found use as an alternative antigen for diagnostic BV serology.^17,25,28 Despite the virus''s similarity to BV, HVP2 infections have never been reported in humans. Consequently, HVP2 is rated as a BSL2 pathogen and, as such, HVP2 can be used under BSL2/ABSL2 containment. This study was conducted to assess the potential use of HVP2 as a surrogate model system for predicting the sensitivity of BV to antiviral drugs.     

LPS induces interleukin-6 and interleukin-8 but not tumor necrosis factor-alpha in human adipocytes

Adipose tissue-derived cytokines are presumably involved in obesity-associated pathologies including type 2 diabetes and atherosclerosis. Here we studied the lipopolysaccharide (LPS)-induced expression dynamics of tumor necrosis factor-alpha (TNFalpha), interleukin-6 (IL-6), IL-8 and IL-10 in human adipose tissue biopsies, in preadipocyte-derived adipocytes, and in mesenchymal stem cell (MSC)-derived adipocytes. TNFalpha, IL-6, IL-8 and IL-10 secretions by adipose tissue explants were increased 5.5-, 19.5-, 3.5- and 12.5-fold, respectively, by LPS (1 microg/mL) administration. Concordantly, IL-6 and IL-8 release was dose-dependently induced in MSC-derived adipocytes by LPS (>10 pg/mL). In contrast, TNFalpha and IL-10 remained undetectable even at the highest LPS dose (1 microg/mL) after 24h. In MSC- and preadipocyte-derived adipocytes, respectively, exposure to LPS evoked a weak and transient induction of TNFalpha mRNA whereas induction of IL-6 and IL-8 mRNA were pronounced and sustained for at least 24h. Basal glucose uptake, lipolysis and IL-6 mRNA were induced by exogenous TNFalpha (10 ng/mL) but not by IL-6 (10 ng/mL), IL-8 (100 ng/mL) and IL-10 (20 ng/mL). In this adipocyte model TNFalpha induces well known metabolic effects, but together with previous reports these data suggest that inflammation-induced TNFalpha may derive from non-adipocyte sources in adipose tissue, likely to be macrophages.     

Antagonist and agonist activities of the mouse agouti protein fragment (91-131) at the melanocortin-1 receptor.

Antagonist and agonist activities of chemically synthetized mouse agouti protein fragment (91-131) (AP91-131) at the melanocortin type-1 receptor (MC1-R) were assessed using B 16-F1 mouse melanoma cells in vitro and the following assay systems: (i) receptor binding, (ii) adenylate cyclase, (iii) tyrosinase, (iv) melanin production, and (v) cell proliferation. In competition binding studies AP91-131 was about 3-fold less potent than the natural agonist alpha-melanocyte-stimulating hormone (alpha-MSH) in displacing the radioligand [125I]-[Nle4, D-Phe7]-alpha-MSH (Ki 6.5 +/- 0.8 nmol/l). Alpha-MSH-induced tyrosinase activation and melanin production were completely inhibited by a 100-fold higher concentration of AP9 l -131; the IC50 values for AP91-131 in thetwo assay systems were 91 +/- 22 nM and 95 +/- 15 nM respectively. Basal melanin production and adenylate cyclase activity in the absence of agonist were decreased by AP91-131 with IC50 values of 9.6+/-1.8 nM and 5.0+/-2.4 nM, respectively. This indicates inverse agonist activity of AP91-131 similar to that of native AP. The presence of 10 nM melanin-concentrating hormone (MCH) slightly potentiated the inhibitory activity of AP91-131 in the adenylate cyclase and melanin assays. On the other hand, AP91-131 inhibited cell growth similar to alpha-MSH (IC50 11.0 +/- 2.1 nM; maximal inhibition 1.8-fold higher than that of alpha-MSH). Furthermore, MC1-R was down-regulated by AP91-131 with about the same potency and time-course as with alpha-MSH. These results demonstrate that AP91-131 displays both agonist and antagonist activities at the MC1-R and hence that it is the cysteine-rich region of agouti protein which inhibits and mimics the different alpha-MSH functions, most likely by simultaneous modulation of different intracellular signalling pathways.     

金属框架结构材料MOF-199对漆酶的固定化及其性质

以金属框架结构材料MOF-199为载体对漆酶进行固定化,并对固定化酶的性质进行初步研究。首先,以3-氨基丙基三乙氧基硅烷对载体MOF-199进行表面氨基化修饰,再用戊二醛对载体进行活化,最后对漆酶进行固定化。固定化条件优化结果表明:在漆酶质量浓度0.3 g/L,戊二醛用量1%(体积分数),pH 4.8下固定7 h,制得固定化酶活性最高。对固定化酶的研究发现:最适反应温度为40℃,最适pH为5.2,在连续操作7次后,固定化酶的活力仍能保持在51%。固定化漆酶热稳定性,pH耐受性,贮存稳定性均明显高于游离漆酶。     

Mycophenolic acid reverses TGF beta‐induced cell motility,collagen matrix contraction and cell morphology in vitro

The aim of this study was to elucidate functional and molecular effects of mycophenolic acid (MPA) on non‐lymphatic, kidney epithelial cells treated with transforming growth factor (TGF). MPA effects were studied using HK2 cells incubated with EGF and TGF. The reversibility of these effects was verified using guanosine and 8‐aminoguanosine. The following assays were applied: cell proliferation, viability, collagen matrix contraction, scratch wound closure, spindle index, FACS with anti‐CD29 and anti‐CD326, promoter demethylation of RAS protein activator like 1 (RASAL1), as well as gene expression of RASAL1, integrin 1ß (ITGB1) (CD29) and epithelial cell adhesion molecule (EpCam) (CD326). Cell proliferation was inhibited by increasing concentrations of MPA, whereas neither apoptosis nor cytotoxicity was detected. Stimulation with EGF and/or TGF led to a significant collagen matrix contraction that was successfully inhibited by MPA. In addition, scratch wound closure was inhibited by incubation with TGF alone or with EGF. Under the same conditions, cell morphology (spindle shape) and molecular phenotype (ITGB1^HighEpCam^Low/ITGB1^LowEpCam^High) were both significantly changed, suggesting an epithelial to mesenchymal transformation. Cell morphology and motility, as well as molecular phenotype, were reversible after MPA treatment with TGF transformation in both presence/absence of EGF, thereby suggesting a correlation with the previously described antifibrotic effects of MPA. Dysregulation of TGF signal transduction appears to be related to progression of fibrosis. A TGF‐transformed kidney epithelial cell line derived from human proximal tubules was used to study whether the immunosuppressive drug: MPA possesses any functional or molecular antifibrotic effects. Functional and morphological in vitro changes induced by both the TGF and epithelial‐growth‐factor were reversible by treatment with MPA. An inhibitory effect of MPA on the TGF pathway appears to be responsible for the previously described antifibrotic effects of the MPA in the COL4A3‐deficient mouse model of renal fibrosis. Copyright © 2015 John Wiley & Sons, Ltd.